[9] [12] Other significant risks include acute pancreatitis (patients should report severe, persistent abdominal pain with or without vomiting), gallbladder disease (watch for right upper quadrant pain, fever, jaundice), acute kidney injury (particularly with severe gastrointestinal symptoms causing dehydration), and hypoglycemia when used with insulin or sulfonylureas
Discontinuation rates within the first year are consistently reported between approximately 45 and 75% (Sikirica et al., 2017
Phase Therapeutic range Weeks Weeks 17-20 Weekly Dose 9 mg Notes Phase 3 target dose for many TRIUMPH arms
GLP-1 receptor agonists stimulate insulin secretion and slow stomach emptying, which theoretically could affect pancreatic function in susceptible individuals
Results announced in September 2025 and published in The Lancet in February 2026 demonstrated orforglipron's superiority over oral semaglutide on both HbA1c reduction (approximately 2.2 vs 1.4 percentage points) and weight loss (approximately 9.2% vs 5.3%)